Installation and renewal of manufacturing equipment and construction of a quality control building at the Shizuoka Plant
First written in FY2018. 4 of 7 entries say "Advanced", first in FY2019. Latest entry: FY2026-H1.
Kaken Pharmaceutical moved to the "Worse" side of this theme in 2025.
1 other company's latest entry also says "Softened".
- FY2026-H1SoftenedAnnual report
「Shizuoka Facility (Fujieda, Shizuoka Prefecture) Pharmaceuticals Replacement Pharmaceutical production equipment April 2025 However, the plan has not been completed because some production equipment and other facilities are still being tested. Full-scale operations are scheduled to begin in fiscal 2025.」
The replacement of pharmaceutical production equipment at the Shizuoka Facility was stated to have an April 2025 completion date, but the plan remains incomplete because some equipment is still being tested, with full-scale operations scheduled to begin in fiscal 2025. - FY2025-H1AdvancedAnnual report
「Shizuoka Facility (Fujieda, Shizuoka Prefecture) Pharmaceuticals Replacement Pharmaceutical production equipment 3,240 1,053 Internal funds January 2024 January 2025 Expansion of production capacity」
For the replacement plan for pharmaceutical production equipment at the Shizuoka Facility, total planned investment was ¥3,240 million and ¥1,053 million had already been paid. Completion in January 2025 and the objective of expanding production capacity continue to be indicated. - FY2023-Q3AdvancedAnnual report
「Shizuoka Facility (Fujieda, Shizuoka Prefecture) Pharmaceuticals Replacement Production equipment 2,845 2 Internal funds January 2024 January 2025 Expansion of production capacity」
A replacement plan for the production equipment at the Shizuoka Facility was newly finalised, with planned investment of ¥2,845 million, work scheduled to begin in January 2024 and be completed in January 2025, and the objective of expanding production capacity. - FY2022AdvancedAnnual report
「The main capital investment during the fiscal year totalled ¥3,003 million, focused on the installation and renewal of manufacturing equipment at the Shizuoka Plant.」
The installation and renewal of manufacturing equipment at the Shizuoka Plant continued, with ¥3,003 million invested in the pharmaceutical business. This was an increase from ¥1,862 million in the previous fiscal year. - FY2021RestatedAnnual report
「The main capital investment during the fiscal year totalled ¥1,862 million, focused on the installation and renewal of manufacturing equipment at the Shizuoka Plant.」
The installation and renewal of manufacturing equipment at the Shizuoka Plant continued, with ¥1,862 million invested in the pharmaceutical business. - FY2019AdvancedAnnual report
「The main capital investment during the fiscal year totalled ¥2,286 million, focused on the installation and renewal of manufacturing equipment and construction of a quality control building at the Shizuoka Plant.」
Capital investment, including the installation and renewal of manufacturing equipment at the Shizuoka Plant, continued. The quality control building was completed in October 2018. Capital investment in the pharmaceutical business totalled ¥2,286 million. - FY2018First statedAnnual report
「The main capital investment during the fiscal year totalled ¥1,874 million, focused on the installation and renewal of manufacturing equipment and construction of a quality control building at the Shizuoka Plant.」
The installation and renewal of manufacturing equipment and construction of a quality control building at the Shizuoka Plant were specifically reported for the first time as ¥1,874 million of capital investment during the year.